From Seekingalpha · SA Transcripts · · 40s
Helus Pharma Discusses Mental Health Drug Strategy
Helus Pharma reveals Phase 3 plans for mental health drugs targeting serotonin pathways.
In brief
Helus Pharma reveals Phase 3 plans for mental health drugs targeting serotonin pathways. Helus Pharma announced Phase 3 clinical trials for novel serotonergic agonists to treat mental health conditions. Originally reported by Seekingalpha.
Helus Pharma CEO
Helus Pharma CEO Michael Halstead discussed clinical pipeline and Phase 3 strategies for novel serotonergic agonists in mental health.
Conference Participants
The call included CEO Michael Halstead, Chief Medical Officer Amir Inamdar, and Senior VP of Medical Affairs Ken Kramer.
Forward-Looking Statements
The company warned that forward-looking statements may differ materially from actual results and are subject to risks.
In short
Helus Pharma announced Phase 3 clinical trials for novel serotonergic agonists to treat mental health conditions.
